Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study

被引:36
作者
Ikeda, Satoshi [1 ]
Arita, Machiko [1 ]
Misaki, Kenta [2 ]
Mishima, Shohei [1 ]
Takaiwa, Takuya [1 ]
Nishiyama, Akihiro [1 ]
Ito, Akihiro [1 ]
Furuta, Kenjiro [1 ]
Yokoyama, Toshihide [1 ]
Tokioka, Fumiaki [1 ]
Noyama, Maki [1 ]
Yoshioka, Hiroshige [1 ]
Ishida, Tadashi [1 ]
机构
[1] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama 7108602, Japan
[2] Kurashiki Cent Hosp, Dept Rheumatol, Kurashiki, Okayama 7108602, Japan
来源
SPRINGERPLUS | 2015年 / 4卷
关键词
Interstitial lung disease; Malignancy; Polymyositis; Dermatomyositis; Clinically amyopathic dermatomyositis; IDIOPATHIC INFLAMMATORY MYOPATHIES; POPULATION-BASED COHORT; SINE MYOSITIS; CANCER; RISK; AUTOANTIBODIES; PNEUMONITIS; SPECTRUM; LINK;
D O I
10.1186/s40064-015-1013-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The aims of this study were to retrospectively review Japanese consecutive cases of polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM), focusing on interstital lung disease (ILD) and malignancy, and to document any differences in the incidence, clinical features, and impact on prognosis among patients with PM, DM, and CADM. We retrospectively reviewed 62 consecutive patients diagnosed with PM, DM, and CADM according to Bohan and Peter's criteria (PM/DM) and Sontheimer's criteria and Gerami's criteria (CADM), focusing on ILD and malignancy. ILD occurrence rates were 48 % (11/23) in patients with PM, 46 % (11/24) in DM, and 100 % (15/15) in CADM. Malignancy occurred during diagnosis or the observation period in 14 patients; 86 % were without ILD, and 64 % were DM without ILD. Multivariate logistic regression analysis showed that the risk of newly diagnosed malignancy was significantly lower in patients with ILD [odds ratio, 0.0688; 95 % confidence interval (CI), 0.00127-0.372; p = 0.00190] and significantly higher in patients with DM (odds ratio, 5.21; 95 % CI, 1.17-23.1; p = 0.0299) than in other patients. Patients with malignancies had shorter survival than those without malignancies; no clinically meaningful difference in survival was observed among the different myositis types and for presence of ILD. In CADM-ILD, 80 % fatal cases died from refractory ILD = 90 days from the first visit; neither death nor recurrence occurred subsequently. In conclusion, a positive association between DM and malignancy and a negative association between ILD and malignancy were noted. In the present study, malignancy was a predictor of poor long-term prognosis, but ILD were not. ILD associated with CADM contributed greatly to poor short-term prognosis, but neither death nor recurrence occurred subsequently.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis
    Gan Yu-Zhou
    Zhang Li-Hua
    Ma Lin
    Sun Feng
    Li Yu-Hui
    An Yuan
    Li Zhan-Guo
    Ye Hua
    中华医学杂志英文版, 2020, 133 (06) : 644 - 649
  • [42] A Japanese-American female with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
    Takada, Toshinori
    Asakawa, Katsuaki
    Barrios, Roberto
    CLINICAL RHEUMATOLOGY, 2021, 40 (03) : 1159 - 1165
  • [43] Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study
    Ji, Qiang
    Pan, Wenping
    Zhang, Di
    Hou, Yanfeng
    Wang, Zhankui
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [44] Efficacy of infliximab plus conventional therapy in dermatomyositis/polymyositis with interstitial lung disease: a prospective cohort study
    Ma, Jingjing
    Sun, Jianmei
    Wang, Yanjie
    Li, Guizhi
    Li, Ming
    Zhu, Yun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 6819 - 6827
  • [45] Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis
    Shimojima, Yasuhiro
    Ishii, Wataru
    Matsuda, Masayuki
    Kishida, Dai
    Ikeda, Shu-ichi
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2017, 23 (02) : 87 - 93
  • [46] Clinical impact of antineutrophil cytoplasmic antibody positivity on the occurrence of interstitial lung disease in patients with polymyositis/dermatomyositis
    Ha, Jang Woo
    Pyo, Jung Yoon
    Ahn, Sung Soo
    Song, Jason Jungsik
    Park, Yong-Beom
    Lee, Sang-Won
    ANNALS OF PALLIATIVE MEDICINE, 2022, : 3181 - 3192
  • [47] Successful management of interstitial lung disease in dermatomyositis complicated by malignancy: a case-based review
    Katakura, Tokio
    Shirai, Tsuyoshi
    Sato, Hiroko
    Ishii, Tomonori
    Fujii, Hiroshi
    RHEUMATOLOGY INTERNATIONAL, 2024, 44 (09) : 1781 - 1788
  • [48] Prognostic analysis of MDA5-associated clinically amyopathic dermatomyositis with interstitial lung disease
    Wang, Wen
    Sun, Xiang
    Xu, Yan
    Tan, Wenfeng
    Liu, Ye
    Zhou, Jun
    IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (06)
  • [49] Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis
    Zhu, Dingxian
    Qiao, Jianjun
    Tang, Shunli
    Pan, Yunlei
    Li, Sheng
    Yang, Changyi
    Fang, Hong
    RHEUMATOLOGY, 2021, 60 (08) : 3896 - 3903
  • [50] Clinical parameters of therapeutic apheresis induction in clinically amyopathic dermatomyositis patients with rapid progressive interstitial lung disease
    Kagitani, Maki
    Nomi, Hayahito
    Azuma, Haruhito
    THERAPEUTIC APHERESIS AND DIALYSIS, 2023, 27 (01) : 152 - 158